| Name | Title | Contact Details |
|---|
The DHA is a joint, integrated Combat Support Agency that enables the Army, Navy, and Air Force medical services to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime. The DHA supports the delivery of integrated, affordable, and high quality health services to 9.5 million Military Health System beneficiaries and is responsible for driving greater integration of clinical and business processes across the MHS. The DHA oversees the delivery of health care services like the TRICARE Health Plan, pharmacy, public health, and health information technology. DHA carries out these operations using a global health care network of military and civilian medical professionals and more than 400 military hospitals and clinics. This network strengthens the delivery of health care to MHS beneficiaries by merging proven clinical and business practices and emphasizing the experience of the patient. Exciting changes are taking place as we are in the process of reorganizing how we manage the military`s medical centers, hospitals and clinics around the world, shifting administration and management responsibility for these facilities from the Army, Navy and Air Force to the Defense Health Agency. A single integrated system will support improvements to the readiness of our operational and medical forces to meet our missions around the world, while providing outstanding care to all of those who depend on us, on the battlefield and at home.
Decatur Vein Clinic is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
American Clinical Research Services is a company that provides clinical research services.
BSI was founded by Judith C. McDowall in 1985 to prepare documentation for FDA regulatory submissions. BSI began preparing peer reviewed technical reports for the National Toxicology Program in 1989. We obtained and have retained this prestigious
ForSight VISION5, Inc. (www.forsightvision5.com), was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5`s lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. The Helios insert is restricted to investigational use only and has not been approved by the Food and Drug Administration or any other regulatory authority for commercial distribution.